Valeo Pharma (CSE: VPH) President and CEO Steve Saviuk joined Steve Darling from Proactive Vancouver with news the company has entered into a collaboration and licensing agreement with Ingenew Pharma for the development, manufacture and commercialization of Hesperco. Saviuk tells Proactive more about the deal and more about Hesperco and also when they are hoping to hear from Health Canada.
Valeo Pharma applies to Health Canada to licence immune system support product Hesperco
Quick facts: Valeo Pharma Inc.
Price: 1.43 CAD
Market Cap: $83.04 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE